Abstract library

133 results for "90Yttrium".
#1154 Selective Internal Radiation Therapy (SIRT) Radioembolisation with 90 Yttrium in Patients with Unresectable Liver Neuroendocrine Metastases in a Specialized Center. An Initial Report
Introduction: Most patients with neuroendocrine tumors present liver metastases at some point of the clinical course. Liver directed treatment, such as 90 Yttrium is a method of treatment used in patients with non-resectable liver lesions, which is effective in the control of symptoms and tumor growth.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Juan Manuel O'Connor
#2013 Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yittrium-90 PET Scan
Introduction: 90Y is commonly used in PRRT for NET. It has no gamma photon in its emission that significantly limits post-therapy imaging and dosimetry. Other than Bremsstrahlung imaging which bears hereditary drawbacks of poor resolution, PET scan has been used for post-PRRT imaging. However, in daily clinical practice, due to extremely low abundance of positron emission per decay and patient’s intolerability of prolonged scan time, it is very difficult to obtain a scan with decent quality.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Doctor Sean X Yan
Authors: Yan S X, Lim G K, ...
#768 Long-Term Haematological and Renal Toxicity of 90Yttrium-DOTA-Octreotate in the Treatment of Advanced Neuroendocrine Tumors(NETs)
Introduction: Peptide receptor radiation therapy (PRRT) is an established treatment for advanced NETs. Renal/haematological toxicity are recognised adverse effects.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: DR VINCENT Cheung
#1717 Yttrium-90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis
Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Bernardo Marques
#1720 Yttrium90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis
Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Bernardo Marques
#81 Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): our experience in a multidisciplinary team in a university hospital
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a low incidence and prevalence representing < 2% of all gastrointestinal tumors with a heterogeneous biological behavior and an often complex management.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jose Manuel Cabezas-Agricola
#1416 Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Advanced Bronchial Neuroendocrine Tumours
Introduction: There is not established treatment pathway in advanced bronchial neuroendocrine tumours(bNETs).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
Keywords: PRRT, bronchial NETs
#450 Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multiinstitutional Cancer Registry
Introduction: Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor expressing neuroendocrine tumors. However, published data results mainly from retrospective monocentric studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Dr. Dieter Hörsch
#15 Gastroduodenal ulceration associated with radioembolization for the treatment of liver malignancies, a newly observed complication: Institutional experience and review of the literature
Introduction: Microsphere radioembolization is a method of delivering radiation therapy directly to tumors, thereby minimizing toxicity to adjacent structures. Despite the relatively high precision of this modality, numerous adverse effects have been recognized. One particularly untoward complication is the development of severe gastroduodenal ulceration.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Steven Naymagon
#2023 International Multicentre Retrospective Study on the Safety of Radioembolization with Yttrium-90 Resin Microspheres after Systemic Radionuclide Therapy in Neuroendocrine Tumors
Introduction: In the treatment metastatic neuroendocrine tumours (mNET) safety concerns exist when treating patients with radioembolization (RE) after prior systemic radionuclide therapy (SRT)
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Arthur Braat